Back to Search Start Over

Inhibitory effects of NSAID-conjugated SN-38 on the viability of A549 Non-small cell lung cancer cells.

Authors :
Kwon HW
An J
Kim JS
Kang IC
Source :
Biochemistry and biophysics reports [Biochem Biophys Rep] 2023 Jul 23; Vol. 35, pp. 101517. Date of Electronic Publication: 2023 Jul 23 (Print Publication: 2023).
Publication Year :
2023

Abstract

The goal of this paper was to look into the anti-tumor mechanism of Non-Steroidal Anti-Inflammatory Drug (NSAID)-conjugated SN-38 Prodrug in A549 lung cancer cells. We found that Indomethacine-SN-38 (IndoSN-38) and Naproxen-SN-38(NaproSN-38) as a theranostic prodrug targeting cyclooxygenase-2(COX-2) in cancer cells inhibited A549 cell viability in a dose-dependent fashion. IndoSN-38 and NaproSN-38 inhibited A549 cell viability in a dose-dependent fashion. The suppression of A549 cell viability was due to induction of the cell apoptosis by enhancing the activities of Caspase 3 and Caspase 8. The cell cycle arrest of sub-G1 was found in the cells treated with IndoSN-38 or NaproSN-38. Collectively, these data suggested that the anti-proliferative activities of the NSAID-conjugated SN-38 prodrugs were due to promotion of cell death and arresting the cell cycle which was similar with those of SN-38.<br />Competing Interests: The authors declare that they have no competing interests.<br /> (© 2023 Published by Elsevier B.V.)

Details

Language :
English
ISSN :
2405-5808
Volume :
35
Database :
MEDLINE
Journal :
Biochemistry and biophysics reports
Publication Type :
Academic Journal
Accession number :
37521373
Full Text :
https://doi.org/10.1016/j.bbrep.2023.101517